Octeta Therapeutics

Octeta Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and degenerative diseases by targeting mitochondrial function. The company's lead candidate, MSDC-0602K, is a second-generation mitochondrial pyruvate carrier (MPC) modulator designed to regulate metabolic pathways without the side effects associated with first-generation insulin sensitizers. Octeta is primarily advancing its pipeline for the treatment of non-alcoholic steatohepatitis (NASH) and has explored applications in Type 2 diabetes and neurodegenerative disorders like Parkinson's disease. By modulating the entry of pyruvate into the mitochondria, the company aims to address the underlying metabolic imbalances that drive chronic disease progression.